Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection.
Carreño V, Quiroga JA. J Viral Hep 1997; 4 (Suppl.2): 83-86.
Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV-RNA and liver enzyme levels.
Caramelo C, Bartolomé J, Albalate M, de Sequera P, Navas S, Bermejillo T, Oliva H, Marriott E, Ortiz A, Ruiz Tuñón C, Casado S,Carreño V. Kidney Int 1996; 50: 2027-2031.
Tratamiento de las hepatitis crónicas por virus B y C
Carreño V, Quiroga JA. Farm Hosp 1996; 20: 324-327.
Virus delta de la hepatitis
Madejón A,Carreño V. En: Tratado de Hepatología, Tomo I, Sección IV: Hepatitis Virales, Capítulo 29J.MHerrerías, ADíaz, MJiménez EdsSevilla, 1996; 353-364.
HGV in coagulation-factor concentrates
García-Trevijano ER, López-Alcorocho JM, Quintana M, Hernández F,Carreño V. Lancet 1996; 348: 1032.
Hepatitis E virus seroprevalence in acute viral hepatitis in a developed country confirmed by supplemental assay.
Quiroga JA, Cotonat T, Castillo I,Carreño V. J Med Virol 1996; 50: 16-19.
ltimos avances en hepatología.
Carreño V.Hepatol Clin 1996; 4: 125-142.
Distribution of the predominant hepatitis B virus precore variants in hepatitis B e antigen-positive children and their effect on treatment response.
Cabrerizo M, Bartolomé J, Ruíz-Moreno M, Otero M, López-Alcorocho JM,Carreño V. Pediatric Res1996; 39: 980-984.
New and forthcoming therapies for viral hepatitis.
Carreño V, Quiroga JA. J Hepatol 1996; 24 (Suppl2): s74-s76.
ltimos avances en hepatología.
Carreño V.Hepatol Clin 1996; 4: 47-70.
Relationships between plasma ferritin and aminotransferase profile in haemodialysis patients with hepatitis C virus.
Caramelo C, Albalate M, Bermejillo T, Navas S, Ortiz A, de Sequera P, Casado S,Carreño V. Nephrol Dial Transpl 1996; 11: 1792-1796.
Granulocyte-Macrophage Colony-Stimulating Factor as Adjuvant Therapy for Interferon-a Treatment of Chronic Hepatitis C
Carreño V, Parra A, Navas S, Quiroga JA. Cytokine 1996; 8: 318-322.
